AstraZeneca PLC
NASDAQ:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
NASDAQ:AZN
Watchlist
Price: 65.35 USD 1.41% Market Closed
Market Cap: 202.6B USD
Have any thoughts about
AstraZeneca PLC?
Write Note

Gross Margin
AstraZeneca PLC

82.2%
Current
78%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
82.2%
=
Gross Profit
40.4B
/
Revenue
49.1B

Gross Margin Across Competitors

Country UK
Market Cap 159B GBP
Gross Margin
82%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.6T DKK
Gross Margin
85%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 197.2B CHF
Gross Margin
73%
Country CH
Market Cap 169.7B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
Country IE
Market Cap 147.1B USD
Gross Margin
68%
No Stocks Found

AstraZeneca PLC
Glance View

Market Cap
202.6B USD
Industry
Pharmaceuticals

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
87.06 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
82.2%
=
Gross Profit
40.4B
/
Revenue
49.1B
What is the Gross Margin of AstraZeneca PLC?

Based on AstraZeneca PLC's most recent financial statements, the company has Gross Margin of 82.2%.